




The relative strengths and weaknesses of Pharmacyclics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pharmacyclics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Pharmacyclics INC is the variable Other Expenses, reducing the Economic Capital Ratio by 5.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 379%, being 136% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	740,801
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	87,631
Liabilities, Non-Current	1,472
Other Assets	2,479
Other Compr. Net Income	-4.0
Other Expenses	108,238
Other Liabilities	52,025
Other Net Income	-129
Other Revenues	260,510
Property and Equipment	25,471
Research and Development	85,133
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	768,751
Liabilities	141,128
Expenses	193,371
Revenues	260,510
Stockholders Equity	627,623
Net Income	67,010
Comprehensive Net Income	67,008
BaseVar	681,946
ECR before LimitedLiability	315%
Economic Capital Ratio	379%